Breaking News
Get 45% Off 0
💰 With a 129% YTD gain in the bag, these are our AI’s top global picks for March
Read now

Top Analyst Reports for UnitedHealth, Procter & Gamble & CVS

By Zacks Investment ResearchStock MarketsDec 10, 2021 01:25AM ET
www.investing.com/analysis/top-analyst-reports-for-unitedhealth-procter--gamble--cvs-200611218
Top Analyst Reports for UnitedHealth, Procter & Gamble & CVS
By Zacks Investment Research   |  Dec 10, 2021 01:25AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
INFY
+0.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CVS
+1.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
UNH
+1.18%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Friday, December 10, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. (UNH), The Procter & Gamble Company (PG), and CVS Health Corp (NYSE:CVS). (CVS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of UnitedHealth have outperformed the Zacks Medical Insurance industry over the past year (+42.4% vs. +36.5%). The Zacks analyst believes that UnitedHealth's continued strong growth at Optum as well as UnitedHealthcare segments have been driving revenues. Strength in government business and a strong capital position are other positives.

This momentum is likely to continue in the years ahead, on the back of its strong market position that continues to be driven by new deals, renewed agreements and expansion of service offerings. Its solid health services segment provides diversification benefits. Weakness in the commercial business and overvaluation concerns remain as the major concerns though.

(You can read the full research report on UnitedHealth here >>>)

Procter & Gamble shares have gained +13% in the year to date period against the Zacks Soap and Cleaning Materials industry’s gain of +3.4%. The Zacks analyst believes that the nature of Procter & Gamble’s products has led to increased consumer demand for its hand soaps, detergents and surface cleaning products since the beginning of the pandemic.

PG benefited from robust top-line growth, in first-quarter fiscal 2022, across all segments on the back of robust volume, pricing and mix. Procter & Gamble’s revenues beat estimates for the sixth straight time in the quarter. Higher commodity and freight costs, however, are likely to persist and PG expects impacts of $2.1 billion from input costs and $200 million from freight costs in fiscal 2022.

(You can read the full research report on Procter & Gamble here >>>)

Shares of CVS Health have gained +15.2% in the last six months against the Zacks Retail Pharmacies and Drug Stores industry’s gain of +6.1%. The Zacks analyst believes that CVS Health’s specialty digital solutions for patients has registered a CAGR of 25% in the past two years.

Since the start of the pandemic, CVS has been witnessed a significant growth in specialty orders placed digitally. The consumer-centric digital strategy has become more relevant in the current environment as people use technology more while staying indoors. Rising pressure to reduce reimbursement rates for generic drugs, disappointing retail performance, and stiff competition in the market remain as major concerns though.

(You can read the full research report on CVS Health here >>>)

Other noteworthy reports we are featuring today include Infosys (NYSE:INFY) Ltd. (INFY), Square, Inc. (SQ) and ABB Ltd. (ABB).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>


5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (NYSE:UNH): Free Stock Analysis Report

Procter & Gamble Company The (PG): Free Stock Analysis Report

Infosys Limited (INFY): Free Stock Analysis Report

ABB Ltd (ABB): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Square, Inc. (SQ): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Top Analyst Reports for UnitedHealth, Procter & Gamble & CVS
 

Related Articles

Adam Hamilton
Big US Stocks’ Q4’24 Fundamentals By Adam Hamilton - Mar 07, 2025

The big US stocks dominating markets and investors’ portfolios just finished another earnings season. They reported spectacular collective results including record sales, profits,...

Top Analyst Reports for UnitedHealth, Procter & Gamble & CVS

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email